Kyung Chu on Treating Different Subtypes of the KRAS Mutation

Video

Kyung Chu, RN, NYU Langone Perlmutter Cancer Center, discusses treating patients with different subtypes of KRAS mutation.

Kyung Chu, RN, NYU Langone Perlmutter Cancer Center, discusses treating patients with different subtypes of KRAS mutation.

Typically, EGFR inhibitors are used in lung and colon cancer to treat patients with KRAS mutations. However, this therapy has mixed clinical outcomes for the patients, varying by their mutation subtype. Chu emphasizes that nurses and doctors must use the EGFR inhibitors wisely, and consider the patient’s subtype when deciding on a treatment plan.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
Related Content
Graphic that resembles a stamp of approval reading "FDA Approved"

Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer

Bridget Hoyt
June 11th 2025
Article

The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

Lindsay Fischer
November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Anatomical graphic of a person with a tumor in their left lung

Tarlatamab Supported as Second-Line SOC by DeLLphi-304 in SCLC

Chris Ryan
June 4th 2025
Article

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.

The Vitals

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Lindsay Fischer
October 31st 2023
Podcast

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Illustration of a pancreas on a blue background

Novel ADC Receives FDA Fast Track Designation for Pancreatic Cancer

Sabrina Serani
May 30th 2025
Article

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

Line illustration of lungs with a tumor in the left lung

Sevabertinib Given FDA Priority Review for HER2+ NSCLC

Bridget Hoyt
May 29th 2025
Article

The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell lung cancer.